PDP Pediapharm

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES


Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE:PDP) announces
the termination of its promotional sales agreements with Sanofi Canada for
Suprax(R) and AllerjectO, effective June 30, 2014. Although this will impact the
revenues for the second-half of 2014, it will allow the Corporation to focus its
commercial efforts on its core brands, such as NYDA, a revolutionary treatment
indicated for eradication of head lice and its eggs. Furthermore, the
Corporation is deploying substantial efforts to obtain the approval of one of
its innovative asthma products with the Canadian health authorities. 


Also, Pediapharm is pleased to announce the engagement of Bloom Burton & Co., a
firm dedicated to accelerating monetization for both investors and companies
alike in the healthcare sector. Bloom Burton & Co. will have a specific mandate
to accelerate the Corporation's efforts to complete product acquisitions.
Pediapharm's strategic focus remains to partner with leading healthcare entities
around the world to bring innovative pediatric products to the Canadian market. 


Brian Bloom, President of Bloom Burton & Co. says, "We are proud to partner with
Pediapharm to explore new avenues to leverage the company's unique
infrastructure, expertise and relationships with pediatric physicians and
patient groups. There are tremendous opportunities in the Canadian specialty
pharmaceutical market for both companies and investors, and we view Pediapharm
as a leading emerging company in this sector."


About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and
Camphor. 


About Bloom Burton & Co.

Bloom Burton & Co. is a firm dedicated to accelerating monetization for both
investors and companies alike in the healthcare sector. Bloom Burton has an
experienced team of medical, scientific, pharmaceutical, legal and capital
markets professionals who perform a deep level of diligence, which combined with
a creative and entrepreneurial approach, assists to lead to our clients to the
appropriate monetization events. Bloom Burton and its affiliates provide capital
raising, M&A advisory, equity research, business strategy and product
development consulting and also create and incubate new biotechnology and
healthcare companies. Please visit www.bloomburton.com to learn more.


FORWARD LOOKING STATEMENTS

This news release contains forward-looking statements and other statements that
are not historical. Such forward-looking statements are subject to known and
unknown risks, uncertainties and assumptions that could cause actual results to
vary materially from target results and the results or events predicted in these
forward-looking statements. As a result, investors are cautioned not to place
undue reliance on these forward-looking statements.


The forward-looking statements contained in this news release are made as of the
date of this release. Except as required by applicable law, the Corporation
disclaims any intention and assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Forward-looking information reflects the current
expectations or belief of the Corporation based on information currently
available and such information is subject to a number of assumptions, risks and
uncertainties described in details at pp. 35 to 41 of the Management Information
Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on
SEDAR at www.sedar.com and other risks associated with being a specialty
pharmaceutical company.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sylvain Chretien
President and Chief Executive Officer
Pediapharm Inc.
Tel.: 514-762-2626 ext., 201
E-mail: sylvain.chretien@pedia-pharm.com


Roland Boivin
Chief Financial Officer
Pediapharm Inc.
Tel.: 514-762-2626 ext., 202
E-mail: roland.boivin@pedia-pharm.com

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024